Split History
ETFs Holding IDRA »    IDRA Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Idera Pharmaceuticals is a biopharmaceutical company. Co.'s focus is on its Toll-like receptor, or TLR, agonist, tilsotolimod (IMO-2125), for oncology. Co.'s TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. Co. is developing tilsotolimod, via intratumoral injection, for the treatment of anti-PD1 refractory metastatic melanoma in combination with ipilimumab, an anti-CTLA4 antibody marketed as Yervoy® by Bristol-Myers Squibb Company (BMS). Co. is also evaluating intratumoral tilsotolimod in combination with nivolumab, an anti-PD1 antibody marketed as Opdivo® by BMS, and ipilimumab for the treatment of multiple solid tumors in a Phase 2 trial. According to our IDRA split history records, Idera Pharmaceuticals has had 1 split.
IDRA split history picture
Idera Pharmaceuticals (IDRA) has 1 split in our IDRA split history database. The split for IDRA took place on July 30, 2018. This was a 1 for 8 reverse split, meaning for each 8 shares of IDRA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 125 share position following the split.

When a company such as Idera Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the IDRA split history from start to finish, an original position size of 1000 shares would have turned into 125 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Idera Pharmaceuticals shares, starting with a $10,000 purchase of IDRA, presented on a split-history-adjusted basis factoring in the complete IDRA split history. IDRA split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 08/18/2009
End date: 08/16/2019
Start price/share: $58.08
End price/share: $2.13
Dividends collected/share: $0.00
Total return: -96.33%
Average Annual Total Return: -28.15%
Starting investment: $10,000.00
Ending investment: $366.66
Years: 10.00
Date Ratio
07/30/20181 for 8
IDRA is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

IDXG Split History
IDXX Split History
IGC Split History
ILMN Split History
IMMY Split History
IMNP Split History
IMRS Split History
IMUC Split History
INCY Split History
INFI Split History

Also explore: IDRA shares outstanding history

SINTX Technologies, Inc. (SINT)
Pluristem Therapeutics Inc. (PSTI)
Neuralstem, Inc. (CUR)
Francesca's Holdings Corporation (FRAN)
China Green Agriculture, Inc. (CGA)
Xenetic Biosciences, Inc. (XBIO)
Yuma Energy, Inc. (YUMA)
Avinger, Inc. (AVGR)
Sonoma Pharmaceuticals, Inc. (SOMA)
Hudson Global, Inc. (HSON)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

IDRA Insider Buying

IDRA Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.